GROWTH HORMONE DEFICIENCY (GHD) AND THE IMPORTANCE OF GROWTH HORMONE REPLACEMENT IN TRANSITION FROM LATE ADOLESCENCE TO ADULTHOOD
Guidelines for patients with GHD in transition from pediatric to adult endocrinologist

Abstract: Transitional period (TP) is the time of several years in a person’s life after reaching of final body height, spanning from about the age of 16 to about the age of 26 years. In this period the person reaches a peak in muscle mass and bone mineral density. Growth hormone deficiency (GHD) in the TP leads to reduced bone mineral density and inadequate body composition with reduced muscle mass and increased abdominal fat mass. GHD in TP is also associated with impaired lipid profile, increased insulin resistance and risk for metabolic syndrome. GH replacement during TP has a favorable effect on bone density and quality, on body composition and on cardiovascular health, thus reducing future morbidity and mortality in adulthood. GH replacement is of particular importance for quality of life improvement in the young patients.

To facilitate and optimize the continuance of GH replacement in the TP for the patients treated with GH in childhood, we have comprised these guidelines aimed to improve the communication between pediatric and adult endocrinologists. A closer collaboration between these two services would ensure easier continuance of treatment and follow up for the patients with hypopituitarism in transition to adulthood. The goal of presenting these guidelines is to prevent the drop out of patients with GHD in TP from continuing GH replacement and other relevant hormonal replacement.

Key words: growth hormone deficiency, transitional period, guidelines
Introduction

Transitional period (TP) in a person’s life represents the time from late adolescence until the reaching of full physical and psychosocial maturation into an adult person. This period lasts for several years after the termination of linear growth in height, spanning from the age of 16 to the age of 26 years. Due to physical, metabolic, psychological and social specificities commonly related to the transition from late puberty to adulthood, in the young patients with growth hormone deficiency (GHD) a particular attention needs to be paid to the collaboration between pediatric endocrinologist and “adult” internist endocrinologist. In the patients treated for GHD in childhood, continuance of treatment needs to be reassessed.

Reaching of sufficient body height is only a prerequisite for acquisition of normal body composition. In the past, GH replacement was discontinued when the patient stopped growing and reached the final body height. However, the TP is in fact the period when a peak in muscle mass and bone mineral density is yet to be reached. Development of bone is believed to continue as far as to the age of 30 years. GH deficit in TP results in failure to reach maximal bone mineral density potential and leads to inadequate body composition with reduced muscle mass and increased abdominal fat mass. Lipid profile is also impaired leading to increased risk of metabolic syndrome. Thus the second most important period of GH action, next to its crucial role in childhood, is in fact in the TP. GH replacement in TP has a favourable effect on bone, body composition and cardiovascular health, leading to reduction of future morbidity and mortality in adulthood. An improvement of quality of life was documented during GH replacement in this psychosocial vulnerable period of a person’s life.

When a pediatric endocrinologist concludes that the patient has finalised growth in height, a GH axis reassessment by an adult endocrinologist should follow. It is recommended that prior to retesting GH replacement should be discontinued for 1 to 3 months. One third of patients which have an isolated idiopathic GHD in childhood may recover their GH axis in TP. If the cause of GHD is structural (endocranial tumors, hypothalamic anomalies) or a confirmed genetic mutation (involving transcriptional factors for pituitary region development) then GHD is expected to persist. In such patients, there is usually a complete anterior pituitary hormonal deficiency (affecting ACTH, TSH, FSH/LH) and GH stimulation tests might be unnecessary in the presence of reduced IGF-1 which is sufficient for diagnosing GHD. In other patients, along with IGF-1 assessment, retesting of GH axis with one or two GH stimulation tests is advised. In TP patients we use ITT (insulin tolerance test) and glucagon test. Peak response of GH < 5.1 µg/l in these tests is indicative of GHD. Since TP patients are in the transition from childhood to adulthood, GH replacement doses should be targeted between the recommended doses for these two age groups. Replacement is initiated with lower daily doses (0.3 - 0.5 mg/d GH) and the dose is further titrated.
Growth hormone deficiency (GHD) and the importance of growth hormone...

according to serum IGF-1 values and clinical response to treatment, but rarely exceeds 1.6mg/d. GH replacement dose is individually determined for each patient, aiming for IGF-1 in mid normal age specific range. Followup of GH replacement during TP should include 6-monthly visits for assessment of body weight and height, waist and hip circumference, blood pressure, fasting glucose, HbA1c and lipid profile, and annual visits to assess quality of life using a specific questionnaire - AGHDA-QoL, and to assess thyroid status and serum cortisol level. Body composition and bone mineral density assessment, by using DXA is necessary at baseline and then every 2 to 5 years.

Algorithm for retesting patients with growth hormone deficiency in the transitional period

Guidelines for GHD patient transition from a pediatric endocrinologist to an internist endocrinologist

Mirjana Doknić1,3, Tatjana Milenkovic2, Vera Zdravkovic3,4, Maja Jesic3,4, Sladjana Todorovic2, Katarina Mitrovic2,4, Rade Vukovic2; Study Group for GH treatment in transitional period*

Treatment of patients with growth hormone deficiency (GHD) in the transitional period remains a challenge for both pediatric endocrinologists and “adult” internist endocrinologists. Collaboration between the two services is the key to success in treatment of this group of patients leading to their achievement of full psycho-physical maturity in adulthood.
A patient in transitional period lacks a clear understanding of what to expect from his future care at an adult endocrine service. He or she is usually intimidated for leaving the care of pediatric endocrinologist who treated him or her for years, and for needing to continue the treatment with a new and unfamiliar doctor. Thus the first visits to an adult endocrinologist are crucial to break these fears and close communication with the patient is essential for his or her future treatment. Based on 15 years of experience in the field of transition of patients with GHD in Serbia, we have devised the guidelines for leading both the patients and the caring endocrinologists – pediatricians and internists. The aim was to improve the collaboration between the pediatric and “adult” endocrinologists, and to reduce the fraction of patients who drop out from further follow up and treatment of hypopituitarism in transitional period. The guidelines were adapted from the algorithm for approach to patient in transition from a pediatric to adult care advised by Endocrine Society (www.endocrinetransitions.org).

Guidelines for transition of GHD patients from pediatric to adult endocrinologist care consist of 3 forms: 1) Information for the patients and his or her parents 2) Patient’s clinical data (provided by a pediatric endocrinologist and sent to the internist endocrinologist) 3) Patient’s clinical data after assessment by the adult endocrinologist (provided by the internist endocrinologist and returned to the pediatric endocrinologist who has referred the patient).


1Department for neuroendocrinology, Clinic for endocrinology, diabetes and metabolic diseases, Clinical Centre of Serbia; 2Endocrinology department, Institute for healthcare of mother and child “Dr Vukan Čupić”; 3Medical Faculty, University of Belgrade 4Tiršova University pediatric Clinic; 5Department of endocrinology, Clinic for pediatric internal medicine, Clinical Centre Niš 6Clinic for Endocrinology, Clinical Centre Niš; 7Medical Faculty, University of Niš; 8Clinic for endocrinology, diabetes and metabolic diseases, Clinical Centre of Vojvodina, Novi Sad; 9Institute for health care of children and youth of Vojvodina – Department of Endocrinology, Clinical Center of Vojvodina, Novi Sad; 10Medical Faculty, University of Novi Sad; 11Center for Endocrinology, diabetes and metabolic diseases, Clinical Centre Kragujevac; 12Pediatrics Clinic, Clinical Centre Kragujevac; 13Faculty of medical sciences University of Kragujevac; 14Special hospital for thyroid diseases and metabolic diseases “Zlatibor”; 15Institute for Medical statistics and informactics, Belgrade
1) Information for the patient and his or her parents

NAME AND CONTACT DETAILS OF THE INTERNIST ENDOCRINOLOGIST IN CHARGE**:

Institutional address:

Phone:

Mobile:

e-mail:

**Pediatric endocrinologist provides the contact of the internist to whom the patients in transition is referred.

1. The first appointment with an internist endocrinologist should be scheduled by mobile phone call or e-mail

2. Patient should attend the first meeting with an internist endocrinologist accompanied by his or her parents. All relevant medical records should be brought (discharge letters and pediatric visit notes, MR images). A referral letter for an outpatient visit to internist endocrinologist must be provided by a primary care physician. At this first appointment, the internist endocrinologist will explain the patient and the parents in detail about the reasons for continuing hormonal treatment, and about the risks of discontinuing this treatment. Internist endocrinologist is obliged to answer all relevant questions posed by the patient or the parents regarding the patient’s health condition and treatment. Short term and long term expectations from treatment should be discussed.

3. Hormonal and metabolic investigation is designed through a 3 to 5 day in-hospital stay at an adult endocrine department. A referral letter for in-patient stay must be provided by a primary care physician. During the hospital investigation the following is to be performed:

- Stimulation tests of pituitary reserve assessment (usually two tests)
- DXA- bone mineral density and body composition assessment
- Abdominal and neck ultrasound
- Chest X-ray and profile craniogram
- Hand X-ray (to assess the termination of linear growth)
- Quality of life assessment by questionnaire

If the patients can provide other accommodation in the vicinity of the referral center (Beograd, Niš, Novi Sad, Kragujevac), he needs not stay at the hospital department but must present for 3 to 5 consecutive days at the endocrine department
and be available for the investigation during the morning hours until 12h. In this way patient would be free of commitments in the afternoon until the next morning. This option is also based on the in-hospital referral letter from GP.

4. Patient is discharged with the next appointment scheduled usually within a month to evaluate the results of the performed tests.

5. Based on the test results, a decision is made on the future treatment of the patient. Most patients continue with the treatment initiated by the pediatric endocrinologist. GH replacement doses are much lower for the adults compared to children (0.3-1.0 mg daily). Some patients recover their pituitary function and do not need further hormonal replacement. These are most often patients with isolated GH deficiency.

6. If the replacement hormonal treatment is continuing, the visits to internist endocrinologist are usually scheduled for every 6 months. Stimulation tests are not repeated.

7. Six-monthly appointments are scheduled with the internist endocrinologist. Hormonal status will be analyzed (by a single morning blood sampling, in the patient`s city of residence or at the Endocrinology clinic, as arranged. Serum IGF-1 is analyzed to assess efficacy and safety of the current GH replacement dose.

8. Patient is introduced to the delegated departmental endocrine nurse in charge for his or her training for adequate GH self administration, and for further monitoring of correct self administration.

9. Patient and his or her parents must be familiar with the patient`s treatment, including doses and procedures in special circumstances (e.g. fever over 38C, vomiting, diarrhea, surgical procedures, infections, loss of consciousness, trauma). Patient`s family members must be educated on high dose hydrocortisone administration in such emergencies. They also must be familiar with the nearest ER location or other point of emergency first healthcare contact in order to avoid delay in reacting in the event of emergency.

10. If the patient receives hydrocortisone replacement, he or she needs to always carry an emergency identity card (provided by the internist endocrinologist), assuring that stress doses of i.v. hydrocortisone would be WITHOUT DELAY administered in the event of an emergency (infection, unconsciousness, surgery, trauma).
2) Patient’s clinical data on GHD during childhood

(provided by the pediatrician endocrinologist and sent to the internist endocrinologist)

PATIENT’S FULL NAME______________________________________________

PATIENT’S DATE OF BIRTH ___________________________________________

DATE OF DIAGNOSIS OF HYPOPITUITARISM ______________________________

AGE OF DIAGNOSIS OF HYPOPITUITARISM ______________________________

Present condition: __________________________________________________________________________

Etiology of hormonal deficiency: Congenital □  Genetic analysis Yes □  No □

Tumors □

Tumors of H/H region or brain, trauma: Craiopharyngeoma □  Meduloblastoma □

Germinoma □  Pituitary adenoma □

Astrocytoma □  Perinatal trauma □

Rathke`s cyst □  TBI □

PNET □  Vascular lesions □

Other brain tumors □

Endocranial tumor treatment: Surgery □  Date:

Radiotherapy □  Date (start and end date):

Chemotherapy □  Date:

Number of impaired hormonal axes: Isolated GH deficiency □  FSH/LH deficiency □

ACTH deficiency □  ADH deficiency □

TSH deficiency □

HORMONAL REPLACEMENT (provide current doses prior to the referral to internist endocrinologist):

Growth hormone: When was replacement initiated? __________________ Dose:

When was replacement discontinued? __________________

Hydrocortisone: When was replacement initiated? __________________ Dose::

L-Thyroxine: When was replacement initiated? __________________ Dose:
Sex steroids: When was replacement initiated? ___________________ Dose::  
ADH: When was replacement initiated? ___________________ Dose:

Pituitary reserve tests: test date, type of test, GH peak value, cortisol peak value:

Comorbidites:  

Yes □  No □

Sellar region or endocranial MRI: Date of imaging:  MR finding:

Hand radiography: (bone age determined prior to referral to internist endocrinologist):

Date:  Finding:

Date: Signed by referring pediatrician endocrinologist:
3) Patient’s clinical data – after the evaluation by the internist endocrinologist

(provided by the internist endocrinologist and returned to pediatrician who referred the patient)

After 3 months since the investigation in the referral endocrinology department, internist endocrinologist informs the pediatric endocrinologist of the following:

Was the patient validly evaluated? □ Yes □ No

1. Has GH deficiency and other anterior pituitary hormones deficiency been confirmed? □ Yes □ No

2. Was an initial or control sellar region MRI performed and what are the findings? □ Yes □ No

3. Was DXA (bone densitometry and body composition) performed and what are the results? □ Yes □ No

4. Did the patient psychologically take well the transition from a pediatrician to an adult endocrinologist? □ Yes □ No

5. Did the patient find a job or continue with his or her education? □ Yes □ No

6. What is the emotional status of the patient and motivation for reproduction?

Date: ___________________________ Signed by the internist endocrinologist
References:


4. Inzaghi E, Cianfarani S. The Challenge of Growth Hormone Deficiency Diagnosis and Treatment during the Transition from Puberty into Adulthood.Front Endocrinol (Lausanne), 20; 4:34, 2013

